Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

Chung, Christine H.; Cohen, Ezra E.W.; Cohen, Roger B.; Gilbert, Jill; Hayes, D. Neil; Hayward, Michele C.; Hoskins, Janelle; Krzyzanowska, Monika K.; Lucas, Amy S.; Mehra, Ranee; Moore, Dominic T.; Murphy, Barbara A.; O'Connor, Wendi; Sheikh, Arif; Tanvetyanon, Tawee; Weck, Karen E.; Zhao, Ni

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

Authors: Christine H. Chung
Ezra E.W. Cohen
Roger B. Cohen
Jill Gilbert
D. Neil Hayes
Michele C. Hayward
Janelle Hoskins
Monika K. Krzyzanowska
Amy S. Lucas
Ranee Mehra
Dominic T. Moore
Barbara A. Murphy
Wendi O'Connor
Arif Sheikh
Tawee Tanvetyanon
Karen E. Weck
Ni Zhao
Publication date: 1 January 2012
Publisher
Doi

Abstract

A multicenter, open-label, phase II trial was conducted to evaluate the efficacy, safety, and tolerability of selumetinib in iodine-refractory papillary thyroid cancer (IRPTC)

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Carolina Digital Repository

cdr.lib.unc.edu:7d279137n

Last time updated on 24/11/2020